New

Create, analyze, optimize your ETF portfolio. Start now →

Advertisement
Advertisement
Segment| Data as of 04/24/2026
trending down

Tomorrow's Treatments ETFs

1D perf
-0.34%
1D flows
+$1M
Total AuM
$553M
Total ETFs
8

Aggregate data of 8 funds

Performance

02468101214%Mar 24Mar 31Apr 7Apr 14Apr 21

Flows

-10 M-5 M0 M5 M10 M15 M
1M3MYTD1Y3Y5Y
Perf.+8.27%+0.56%+5.46%+62.60%+56.82%
Flows+$17M+$55M+$90M+$102M+$233M-

Top ETFs in this segment

1D-0.44%1W flows+$17MView
1D-2.35%1W flows-View
1D-1.19%1W flows-View
Advertisement

Just published in Tomorrow's Treatments

View all articles

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Movers in Tomorrow's Treatments

Top
Bottom
Top performers, 1 week1W perf.YTD perf.
BBC
Virtus LifeSci Biotech Clinical Trials ETF+0.20%+19.79%
BBP
Virtus LifeSci Biotech Products ETF-1.46%+6.67%
THNR
Amplify Weight Loss Drug & Treatment ETF-2.19%-2.95%
OZEM
Roundhill GLP-1 & Weight Loss ETF-3.06%-7.99%
CANC
Tema Oncology ETF-3.60%+10.62%
Top inflows, 1 week1W flowYTD flows
SBIO
ALPS Medical Breakthroughs ETF+$17M+$19M
BBC
Virtus LifeSci Biotech Clinical Trials ETF--$2M
BBP
Virtus LifeSci Biotech Products ETF-+$12M
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF--$2M
MEDX
Horizon Kinetics Medical ETF--$799K

Data period: April 17 - 24, 2026

Performance lists exclude leveraged and inverse ETFs

Recently launched ETFs

Inception

Related indexes by ICE

NYFSGIB
NYSE FactSet Global Genomics and Immuno Biopharma IndexView on ICE
NYFSNBM
NYSE FactSet Global Neuro Biopharma and MedTech IndexView on ICE

Latest news about Thematic Investing: Tomorrow's Treatments

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Obesity and Weight-Loss Drugs: A New Thematic ETF Segment?

The ongoing Ozempic and weight-loss drug obsession has investors and ETF issuers turning to new ways of gaining healthcare sector exposure.

Weight-loss-drugs

Two biotech ETFs to watch for the rest of 2022 and beyond

Investors with a high tolerance for risk may seek to gain exposure to the growth potential of the biotech industry. We take a look at two ETFs that have rallied over the last month.

Two biotech ETFs to watch for the rest of 2022 and beyond
Advertisement
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides

Recent educational content

Investors Can Fight Healthcare Inflation with Newly Launched ETFs

Asset TV

The ETF Show - Investors Can Fight Healthcare Inflation with Newly Launched ETFs

Adam Schenck, Principal and Managing Director of Fund Services at Milliman joined The ETF Show to discuss Milliman's first ETFs designed to hedge against rising healthcare inflation.

Asset TV
By Asset TV · April 22, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs April 20, 2026

The ETF Industry saw 14 New Launches, 1 Ticker Change and 16 closures last week.

Tidal
By Tidal · April 22, 2026
The ETF Show - Investors Run to Cash Alternatives as Markets Remain Volatile

Asset TV

The ETF Show - Investors Run to Cash Alternatives as Markets Remain Volatile

Jason England, Portfolio Manager and Fixed Income Strategist from Simplify joined The ETF Show to discuss investor allocations to fixed income as markets continue on their rollercoaster ride.

Asset TV
By Asset TV · April 15, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs March 30, 2026

The ETF Industry saw 33 New Launches, 1 Ticker Change and 9 closures last week.

Tidal
By Tidal · March 31, 2026

Browse all educational columns

The Active Trader Report

Active Trader Report: Use of Leveraged & Inverse ETFs Way Up

Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.

Active Trader Report: Use of Leveraged & Inverse ETFs Way Up